Free Trial

Haleon (HLN) Stock Forecast & Price Target

Haleon logo
$9.27 -0.41 (-4.24%)
Closing price 03:59 PM Eastern
Extended Trading
$9.27 0.00 (0.00%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
5
Buy
5

Based on 10 Wall Street analysts who have issued ratings for Haleon in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 5 have given a hold rating, 3 have given a buy rating, and 2 have given a strong buy rating for HLN.

Consensus Price Target

$12.33
32.96% Upside
According to the 10 analysts' twelve-month price targets for Haleon, the average price target is $12.33. The highest price target for HLN is $13.40, while the lowest price target for HLN is $11.25. The average price target represents a forecasted upside of 32.96% from the current price of $9.27.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for HLN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Haleon and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HLN Analyst Ratings Over Time

TypeCurrent Forecast
9/16/24 to 9/16/25
1 Month Ago
8/17/24 to 8/17/25
3 Months Ago
6/18/24 to 6/18/25
1 Year Ago
9/17/23 to 9/16/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
5 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$12.33$12.33$12.33N/A
Forecasted Upside32.96% Upside27.85% Upside18.00% UpsideN/A
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

HLN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HLN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Haleon Stock vs. The Competition

TypeHaleonMedical CompaniesS&P 500
Consensus Rating Score
2.70
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside30.91% Upside17,884.36% Upside11.27% Upside
News Sentiment Rating
Positive News

See Recent HLN News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/16/2025Barclays
3 of 5 stars
Warren Ackerman
Not Rated
DowngradeOverweightEqual Weight
9/10/2025The Goldman Sachs Group
3 of 5 stars
 UpgradeNeutralBuy
5/27/2025BNP Paribas
4 of 5 stars
M. Omanadze
Not Rated
UpgradeStrong-Buy
5/27/2025BNP Paribas Exane
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeNeutralOutperform$13.40+20.07%
5/9/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeEqual WeightOverweight$11.25+6.38%
3/5/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
3/5/2025HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuyHold
3/3/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingHold
1/8/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformMarket Perform
10/1/2024UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/6/2024Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
3/26/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 08:58 PM ET.


Should I Buy Haleon Stock? HLN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 10, 2025. Please send any questions or comments about these Haleon pros and cons to contact@marketbeat.com.

Haleon
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Haleon plc:

  • Haleon plc recently increased its semi-annual dividend to $0.0555 per share, reflecting a commitment to returning value to shareholders. This increase from the previous dividend indicates strong financial health and a positive outlook.
  • The current stock price is around $12.33, which aligns with analysts' consensus ratings of "Moderate Buy," suggesting potential for growth in the near future.
  • Institutional investors have shown confidence in Haleon plc, with significant increases in holdings by firms such as Hanson & Doremus Investment Management and Bartlett & CO. Wealth Management LLC, indicating strong institutional support.
  • Analysts have recently upgraded Haleon plc's stock ratings, with firms like BNP Paribas and Goldman Sachs expressing optimism about the company's future performance, which can attract more investors.
  • The company operates in the consumer healthcare sector, which has shown resilience and growth potential, especially in the wake of increased health awareness globally.

Haleon
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Haleon plc for these reasons:

  • Despite the positive dividend increase, the payout ratio stands at 28.21%, which, while sustainable, may limit the company's ability to reinvest in growth opportunities.
  • Some analysts have downgraded Haleon plc's stock rating to "Hold," indicating that there may be concerns about the stock's short-term performance and potential volatility.
  • Only 6.67% of the stock is owned by hedge funds and other institutional investors, which may suggest a lack of broader institutional confidence compared to other companies in the sector.
  • The consumer healthcare market is highly competitive, and Haleon plc faces challenges from both established players and new entrants, which could impact its market share and profitability.
  • Recent fluctuations in the stock market may affect investor sentiment, leading to increased volatility in Haleon plc's stock price, which could deter risk-averse investors.

HLN Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Haleon is $12.33, with a high forecast of $13.40 and a low forecast of $11.25.

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Haleon in the last twelve months. There are currently 5 hold ratings, 3 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HLN shares.

According to analysts, Haleon's stock has a predicted upside of 32.96% based on their 12-month stock forecasts.

Over the previous 90 days, Haleon's stock had 1 upgrade and 1 downgrade by analysts.

Haleon has been rated by research analysts at Barclays, and The Goldman Sachs Group in the past 90 days.

Analysts like Haleon less than other "medical" companies. The consensus rating score for Haleon is 2.70 while the average consensus rating score for "medical" companies is 2.78. Learn more on how HLN compares to other companies.


This page (NYSE:HLN) was last updated on 9/16/2025 by MarketBeat.com Staff
From Our Partners